Novartis posts better-than-expected first-quarter sales, raises full-year guidance

1. Novartis reported better-than-expected Q1 sales of $13.2 billion. 2. The company raised its 2025 sales and core income guidance significantly. 3. Sales growth driven by Entresto and Cosentyx; demand for Kisqali rising. 4. Novartis plans to invest $23 billion in U.S. facilities over five years. 5. CEO confident in growth despite potential U.S. pharmaceutical tariffs.